• This record comes from PubMed

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

. 2023 Jul 20 ; 41 (21) : 3689-3699. [epub] 20230606

Language English Country United States Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/pmid37279408

PURPOSE: In GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). The current analysis describes minimal residual disease (MRD) kinetics and any potential predictive value for PFS, as it has not yet been evaluated for ibrutinib + venetoclax treatment. METHODS: Undetectable MRD (uMRD) was assessed by next-generation sequencing at <1 CLL cell per 10,000 (<10-4) and <1 CLL cell per 100,000 (<10-5) leukocytes. PFS was analyzed by MRD status at 3 months after treatment (EOT+3). RESULTS: Ibrutinib + venetoclax achieved deeper uMRD (<10-5) rates in bone marrow (BM) and peripheral blood (PB), respectively, in 40.6% and 43.4% of patients at EOT+3 versus 7.6% and 18.1% of patients receiving chlorambucil + obinutuzumab. Of these patients, uMRD (<10-5) in PB was sustained during the first year post-treatment (EOT+12) in 80.4% of patients receiving ibrutinib + venetoclax and 26.3% receiving chlorambucil + obinutuzumab. Patients with detectable MRD (dMRD; ≥10-4) in PB at EOT+3 were more likely to sustain MRD levels through EOT+12 with ibrutinib + venetoclax versus chlorambucil + obinutuzumab. PFS rates at EOT+12 were high among patients treated with ibrutinib + venetoclax regardless of MRD status at EOT+3: 96.3% and 93.3% in patients with uMRD (<10-4) and dMRD (≥10-4) in BM, respectively, versus 83.3% and 58.7% for patients receiving chlorambucil + obinutuzumab. PFS rates at EOT+12 also remained high in patients with unmutated immunoglobulin heavy-chain variable region (IGHV) receiving ibrutinib + venetoclax, independent of MRD status in BM. CONCLUSION: Molecular and clinical relapses were less frequent during the first year post-treatment with ibrutinib + venetoclax versus chlorambucil + obinutuzumab regardless of MRD status at EOT+3 and IGHV status. Even for patients not achieving uMRD (<10-4), PFS rates remained high with ibrutinib + venetoclax; this is a novel finding and requires additional follow-up to confirm its persistence over time.

Comment In

PubMed

See more in PubMed

National Cancer Institute : SEER Cancer Facts: Chronic Lymphocytic Leukemia. https://seer.cancer.gov/statfacts/html/clyl.html

Eichhorst B, Robak T, Montserrat E, et al. : Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:23-33, 2021 PubMed

National Comprehensive Cancer Network : NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Chronic Lymphocytic Leukemia/Small Lymphocytic, Lymphoma, Version 3. https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf

Goede V, Fischer K, Busch R, et al. : Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370:1101-1110, 2014 PubMed

Amitai I, Gafter-Gvili A, Shargian-Alon L, et al. : Obinutuzumab-related adverse events: A systematic review and meta-analysis. Hematol Oncol 39:215-221, 2021 PubMed

Al-Sawaf O, Zhang C, Lu T, et al. : Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: Extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol 39:4049-4060, 2021 PubMed PMC

Food and Drug Administration : Prescribing Information: Ibrutinib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/205552s035,215063s011lbl.pdf

Food and Drug Administration : Prescribing Information: Venetoclax. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208573s027lbl.pdf

Lu P, Wang S, Franzen CA, et al. : Ibrutinib and venetoclax target distinct subpopulations of CLL cells: Implication for residual disease eradication. Blood Cancer J 11:39, 2021 PubMed PMC

Deng J, Isik E, Fernandes SM, et al. : Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31:2075-2084, 2017 PubMed PMC

Cervantes-Gomez F, Lamothe B, Woyach JA, et al. : Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res 21:3705-3715, 2015 PubMed PMC

Kater AP, Slinger E, Cretenet G, et al. : Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia. Blood Adv 5:5410-5414, 2021 PubMed PMC

Haselager MV, Kielbassa K, Ter Burg J, et al. : Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL. Blood 136:2918-2926, 2020 PubMed

Slinger E, Thijssen R, Kater AP, et al. : Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia 31:2601-2607, 2017 PubMed

Wierda WG, Allan JN, Siddiqi T, et al. : Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: Primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol 39:3853-3865, 2021 PubMed PMC

Hillmen P, Rawstron AC, Brock K, et al. : Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: The CLARITY study. J Clin Oncol 37:2722-2729, 2019 PubMed PMC

Kater AP, Owen C, Moreno C, et al. : Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid 10.1056/EVIDoa2200006 PubMed DOI

Kater AP, Levin MD, Dubois J, et al. : Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): Primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncol 23:818-828, 2022 PubMed

Böttcher S, Ritgen M, Fischer K, et al. : Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30:980-988, 2012 PubMed

Kovacs G, Robrecht S, Fink AM, et al. : Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: Comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol 34:3758-3765, 2016 PubMed

Kater AP, Seymour JF, Hillmen P, et al. : Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: Post-treatment follow-up of the MURANO phase III study. J Clin Oncol 37:269-277, 2019 PubMed

Kersting S, Dubois J, Nasserinejad K, et al. : Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): Primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematol 9:e190-e199, 2022 PubMed

Hallek M, Cheson BD, Catovsky D, et al. : iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood 131:2745-2760, 2018 PubMed

Hamblin TJ, Davis Z, Gardiner A, et al. : Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999 PubMed

Pepper C, Majid A, Lin TT, et al. : Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol 156:499-507, 2012 PubMed

Guo A, Lu P, Galanina N, et al. : Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget 7:4598-4610, 2016 PubMed PMC

Barr PM, Owen C, Robak T, et al. : Up to 8-year follow-up from RESONATE-2: First-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv 6:3440-3450, 2022 PubMed PMC

Fürstenau M, Schilhabel A, Robrecht S, et al. : High resolution assessment of minimal residual disease (MRD) by next-generation sequencing (NGS) and high-sensitivity flow cytometry (hsFCM) in the phase 3 GAIA (CLL13) trial. Blood 138:72, 2021

Eichhorst B, Niemann C, Kater A, et al. : Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA/CLL13 trial. Presented at the 27th Congress of the European Hematology Association (EHA2022), Vienna, Austria, and virtual, June 9-12, 2022 (abstr LB2365)

Kater AP, Wu JQ, Kipps T, et al. : Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase III study. J Clin Oncol 38:4042-4054, 2020 PubMed PMC

Wierda WG, Roberts AW, Ghia P, et al. : Minimal residual disease status with venetoclax monotherapy is associated with progression-free survival in chronic lymphocytic leukemia. Blood 132:3134, 2018

Find record

Citation metrics

Archiving options